New York Life Investment Management LLC Increases Holdings in Solventum Corporation $SOLV

New York Life Investment Management LLC lifted its stake in shares of Solventum Corporation (NYSE:SOLV) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,746 shares of the company’s stock after purchasing an additional 12,773 shares during the quarter. New York Life Investment Management LLC’s holdings in Solventum were worth $2,595,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SOLV. Hilltop National Bank grew its holdings in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum in the third quarter worth about $25,000. Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares in the last quarter. JNBA Financial Advisors boosted its position in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC purchased a new position in Solventum during the second quarter valued at approximately $28,000.

Solventum Stock Up 2.5%

SOLV stock opened at $76.14 on Tuesday. The company’s 50 day moving average is $68.05 and its 200 day moving average is $74.62. The stock has a market cap of $13.19 billion, a price-to-earnings ratio of 9.33, a price-to-earnings-growth ratio of 1.15 and a beta of 0.59. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. Solventum’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Insider Activity

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on SOLV. Mizuho set a $100.00 target price on shares of Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Rothschild & Co Redburn began coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. Wells Fargo & Company reduced their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Finally, Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Eight analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.